Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-02-20, Stock:ABBV, The news for the past five days is as follows:
2019-02-12: NEWS1: AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma.NEWS2: AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma.NEWS3: Better Buy: Gilead Sciences vs. Pfizer.NEWS4: Better Buy: Gilead Sciences vs. Pfizer.NEWS5: AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma.NEWS6: 5 Aristocrats for Stable Income.NEWS7: 5 High-Growth Stocks Undervalued by the Market.NEWS8: 5 High-Growth Stocks Undervalued by the Market.
2019-02-13: NEWS1: AbbVie (ABBV) is a Top Dividend Stock Right Now: Should You Buy?.NEWS2: AbbVie (ABBV) is a Top Dividend Stock Right Now: Should You Buy?.NEWS3: AbbVie (ABBV) is a Top Dividend Stock Right Now: Should You Buy?.
2019-02-14: nan
2019-02-15: NEWS1: AbbVie Inc. -- Moody's announces completion of a periodic review of ratings of AbbVie Inc..NEWS2: [$$] WSJ Tax Guide 2019: The Drug Industry.
2019-02-19: NEWS1: Roche's (RHHBY) BLA for Lymphoma Drug Gets Priority Review.NEWS2: 2 Pharma Stocks in the Middle of an Oncology Sales Explosion.NEWS3: 2 Pharma Stocks in the Middle of an Oncology Sales Explosion.NEWS4: 2 Pharma Stocks in the Middle of an Oncology Sales Explosion.NEWS5: AbbVie stock up 0.2% after FDA grants upadacitinib priority review status.NEWS6: AbbVie Announces New Drug Application Accepted for Priority Review by U.S. FDA for Upadacitinib for Treatment of Moderate to Severe Rheumatoid Arthritis.

Answer: Decrease